Search

canada - search results

If you're not happy with the results, please do another search

0 477

Canada’s bring your own marijuana vapor lounge scene is experiencing impressive growth. Originally a metropolitan city phenom, bring your pot lounges have opened in smaller Canadian communities with great success.

Until recently lounges were a Toronto thing because our politicians and police presumably had better things to do. When conservative city councilor Mark Grimes did request a report on bring your weed lounges, a City of Toronto staff investigation determined lounges were actually Medical Marihuana Inhalation Facilities that had few police problems.

Not exactly what Grimes was seeking.

The example demonstrates how easy it is for a busy body to get their nose out of joint even in a large city. Originally the thinking in a smaller community was there would be too much busybody interference. However, it appears the incredible amount of positive cannabis media coverage has convinced small town busybodies to let lounges be.

In the last six to eight months, lounges have opened in places only a year ago you’d think were not tolerable to cannabis. After an original media storm where police say they’re investigating dies down – nothing happens.

Yet, cannabis is not legal for the majority of Canadians. However, anyone with weed may pay a vapor room cover fee. Typically five dollars. Once inside you’ll see legal medical marihuana patients mingling with recreational enthusiasts, but it’s difficult to distinguish who is legal and who isn’t.

Privacy laws prevent vapor lounge employees from asking if the customer is a legal medical marijuana patient. Cops are struggling to make that determination too and the results are lounges being left alone.

The biggest challenge a would be vapor lounge owner faces is whether their business would be tolerated in their community. It was often thought smaller communities with a bored police chief or politician would harass customers from visiting. (See the Grimes example.)

While it may be still true in some Canadian cities, it’s turning out lounges are becoming very tolerated places to toke.  (See sidebar)

New owners when pressed by media on where the idea for a bring your own weed lounge came from – point their fingers to Toronto and Vapor Central. CEO Chris Goodwin is the brainchild behind vapor lounges and freely spends hours with would be owners. He directs them to my two free guides How To Open A Vapor Lounge as starting point.  http://www.cannabisculture.com/content/2012/03/08/How-Open-Vapor-Lounge

We want people to succeed in opening lounges, but we never thought tinier populated places would tolerate them. This is a signpost Canada is moving quickly to legalization. While we’ve been encouraging people for years, few have opened lounges, but suddenly there’s explosive growth happening.

It appears now is the time to be investing or starting a marijuana vapor lounge. Lounge owners report their respectable startup costs approximately $20,000 – $35,000.

Thirty-two year-old Matt Melanson cashed out his Sobey’s pension ($20,000) and purused his cannabis dreams by opening a lounge.

Opened in January Dr. Greenthumbs in Moncton, NB (population 64,128 and surrounding area population 138,000) is already seeking a much bigger location. Routinely at capacity (60 stoners) this lounge received a good local media news push that was successful capitalized on. While the community is policed by federal officers (RCMP) they have taken no interest in the bring your own bud business.

Two just opened in my former hometown of St. Catharines (population 131,000) and another down Hwy 420 in Niagara Falls (population 49,000). Hamilton is a much larger city (500,000) and it only has three recently opened vapor lounges. None of these communities have had policing problems and all have received positive media.

The positive media is important and owners have to be prepared to live in the local spotlight as the go to expert on cannabis. Besides done properly, it’s good for business.

The first time someone visits a bring your own marijuana vapor lounge, their high just seeing a roomful of enthusiasts socializing while inhaling. It’s a beautiful thing!

Lounges become hubs of cannabis culture and activism.

The first people arriving in any community are the serious enthusiasts, who have gotten word there’s a place to toke. Smart owners’ turn these hardcore heads into regular customers who are tired of having to toke at home or in an alley. By providing them with an awesome chill experience the business will continue to grow because these serious stoners tell their friends during sessions or invite them to session at the weed lounge.

Just like any successful business cultivating regulars will constantly put cash in the till. Expect regulars (daily customers who come in for an hour or more for a session) to become very attached to your brand.

Despite Vapor Central operating at capacity, Wolf of Weed St. had a wonderful experience when he visited on 4/20. He was curious how these venues existed without any police blowback. It’s an incredible experience and it’s cool for us to blaze with worldly stoners too, but unfortunately legal US states appear to currently prevent lounges.

There has to be socializing with legalization! It’s unfathomable to me how Denver has legal grass, but no where to toke it. Canada doesn’t have legal grass, but has places if you happen to be possessing pot you may come on in and consume it.

Marijuana is safer than alcohol therefore lounges are bar harm reduction. Not everyone wants to visit a bar, but they want the socializing and vapor lounges provide this.

Lounge owners’ and employees need to be social stoners because those skills are put to the test in the startup phase to cultivate regulars. Then there can be stoner sport lounges, marijuana and role playing places, internet weed lounges, the possibilities are endless.

Marijuana vapor lounges take people out of their basement or closet. They realize (by seeing) how many different types of people consume cannabis. It’s strange, no longer in dark alley’s, people begin pushing back much harder against prohibition because they see they’re not alone.

Sidebar Compiled By @KatieCannabis

Where The Bring Your Own Cannabis Lounges Are

The Vapor Trails (Niagara Falls)

Puff Dogs Internet Cafe and Vapor Lounge (St. Catharines)

Niagara Cannabis Club (St. Catharines)

Melanheadz (Hamilton)

Vapor Central (Toronto)

Hot Box Cafe (Toronto)

Vape Social (Toronto)

Vape On The Lake (Toronto)

Get Melted (Toronto)

Planet Paradise (Toronto)

Kingston 420 (Kingston)

BuzzON (Ottawa)

Dr. Greenthumbs (Moncton)

High Life Social Club (Halifax)

Farm Assists (Halifax)

Vapes Off Main (Winnipeg )

Vapes On Main (Winnipeg)

Cannabis Culture Lounge (Vancouver)

Seymour Wellness Society (Vancouver)

British Columbia Marijuana Party Vapor Lounge (Vancouver)

The Whiffing Well Oxygen Bar & Vapor Lounge (Vancouver)

Mega ILL (Vancouver)

Mega Chill (Vancouver)

Garden Lounge (Vancouver)


Buy my Marijuana Smoker’s Guidebook The Easy Way to Identify and Enjoy Marijuana Strains http://amzn.to/1avxLOT

 

0 385

One of Canada’s biggest cities is positioned to pass a series of unprecedented regulations for its medical cannabis shops. Amongst the action from the federal government which has made itself an opposing threat of marijuana for any reason.

A set of regulations suggested by Gregor Robertson, Mayor of Vancouver, will make his area the first in Canada to give a clear understanding of the legal gray zone where medical cannabis dispensaries currently conduct business.

The new rules and regulations will limit ownership of these shops to people with no criminal rap sheet, prohibit the sale of edibles, and allow a specific amount where these dispensaries can open, and attach  $35,000 in an annual payment onto the owners.

Vancouver’s city council casted their vote on these actions this past Tuesday, which will potentially be approved. It comes amid an ongoing issue by cannabis producers to obtain a grasp on the profitable Canadian market. Yet, the federal government is firm in maintaining a cap on the burgeoning marijuana business, restricting access and charging crushing fees for marijuana growers.

Although the new Vancouver rules are passed off as a “crackdown” promising to shutter as many as quarter of the dispensaries that are currently doing business in Vancouver, the federal government however is still not happy about it.

0 199

Endexx Delivers Autospense(TM) to Canada

Endexx Signs First International Lease Contract for Dispensing Technology

AutoSpense by Endexx Click here for high-resolution version

CAVE CREEK, AZ–(Marketwired – Mar 24, 2015) – Endexx Corporation (OTC PINK:EDXC) a provider of innovative medical marijuana management and technology solutions, is pleased to announce its first international lease contract in Vancouver, Canada. The Autospense™ unit has shipped after being customized to the Canadian customer’s requirements. The location and customer will be announced at their Grand Opening. The Autospense™ unit has been upgraded to manage international credit/debit card transactions specific to Canada. The new credit card system will be available to all United States units in the future as permitted by law in each jurisdiction.

The lease contract is a for a three year term. The client has indicated its intent to expand up to four to eleven units in both dispensary and clinical settings upon proven performance and market acceptance in their region. Endexx continues to develop its systems to exceed regulatory requirements in all legal jurisdictions to establish compliant and reliable standards. By creating a robust security and compliance platform, Endexx looks to collaborate with other industry leaders.

About Endexx Endexx provides innovative medical marijuana management and technology solutions. The Company has two products that launched in the first half of 2014 — the m3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub database is the first standardized software platform for tracking pharmaceutical grade marijuana to support a Centralized Medical Marijuana Industry Repository and maintain compliance with the laws of the federal government and state and local regulatory bodies. The Autospense™ is a high-tech marijuana inventory control and dispensing machine, which provides up to the minute accounting details and protects the security of the product as well as the patient. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers.www.endexx.com, www.m3hub.com, www.facebook.com/EndexxCorporation

Safe Harbor Notice This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2789315

Contact:
CONTACT:
For further investor and media information
Endexx Corporation
Todd Davis
Chairman & CEO
endexx@endexx.com
480-595-6900

IRTH Communications
Robert Haag
Managing Director
edxc@irthcommunications.com
866-976-4784

0 201

InMed Receives Exemption Status from Health Canada

 

VANCOUVER, British Columbia, March 23, 2015 /PRNewswire/ InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN;OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2014, approving InMed’s application for an exemption under Section 56 of theControlled  Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substance and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems”.

The Office of Controlled Substance licensed dealers has also been notified so that it may import the controlled substances on behalf of InMed.

About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMeds’ Proprietary Platform Technology, Product pipeline and accelerated development pathway are the fundamental value drivers of the Company.

ON BEHALF OF THE BOARD

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

0 147

InMed Receives Exemption Status from Health Canada

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Mar 23, 2015) – InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2015, approving InMed’s application for an exemption under Section 56 of theControlled Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substances and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems.”

The Office of Controlled Substances’ licensed dealer has also been notified so that it may import the controlled substances on behalf of InMed.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.

Craig Schneider, President and Chief Executive Officer

Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about preparing for human clinical studies for lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) and finalizing the development of their respective proprietary delivery systems; and the value drivers of the company. Although such statements are based on management’s reasonable assumptions, such as the continued existence of the exemption, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: the exemption may be removed or become no longer applicable; anticipated clinical studies may not be conducted as planned, or at all; and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities atwww.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact:
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
604.669.7207
604.683.2506
info@inmedpharma.com
www.inmedpharma.com

0 230

Endexx Delivers Autospense(TM) to Canada

Endexx Signs First International Lease Contract for Dispensing Technology

CAVE CREEK, AZ–(Marketwired – Mar 24, 2015) – Endexx Corporation (OTC PINK:EDXC) a provider of innovative medical marijuana management and technology solutions, is pleased to announce its first international lease contract in Vancouver, Canada. The Autospense™ unit has shipped after being customized to the Canadian customer’s requirements. The location and customer will be announced at their Grand Opening. The Autospense™ unit has been upgraded to manage international credit/debit card transactions specific to Canada. The new credit card system will be available to all United States units in the future as permitted by law in each jurisdiction.

The lease contract is a for a three year term. The client has indicated its intent to expand up to four to eleven units in both dispensary and clinical settings upon proven performance and market acceptance in their region. Endexx continues to develop its systems to exceed regulatory requirements in all legal jurisdictions to establish compliant and reliable standards. By creating a robust security and compliance platform, Endexx looks to collaborate with other industry leaders.

About Endexx Endexx provides innovative medical marijuana management and technology solutions. The Company has two products that launched in the first half of 2014 — the m3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub database is the first standardized software platform for tracking pharmaceutical grade marijuana to support a Centralized Medical Marijuana Industry Repository and maintain compliance with the laws of the federal government and state and local regulatory bodies. The Autospense™ is a high-tech marijuana inventory control and dispensing machine, which provides up to the minute accounting details and protects the security of the product as well as the patient. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. www.endexx.com, www.m3hub.com,www.facebook.com/EndexxCorporation

Safe Harbor Notice This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2789315

Contact:
CONTACT:
For further investor and media information
Endexx Corporation
Todd Davis
Chairman & CEO
endexx@endexx.com
480-595-6900

IRTH Communications
Robert Haag
Managing Director
edxc@irthcommunications.com
866-976-4784

0 178

InMed Receives Exemption Status from Health Canada

VANCOUVER, British Columbia, March 23, 2015 /PRNewswire/ InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN;OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2014, approving InMed’s application for an exemption under Section 56 of theControlled  Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substance and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems”.

The Office of Controlled Substance licensed dealers has also been notified so that it may import the controlled substances on behalf of InMed.

About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMeds’ Proprietary Platform Technology, Product pipeline and accelerated development pathway are the fundamental value drivers of the Company.

ON BEHALF OF THE BOARD

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inmed-receives-exemption-status-from-health-canada-300054169.html

0 164

InMed Receives Exemption Status from Health Canada

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Mar 23, 2015) – InMed Pharmaceuticals Inc. (“InMed”) (CSE:IN)(IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2015, approving InMed’s application for an exemption under Section 56 of theControlled Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substances and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems.”

The Office of Controlled Substances’ licensed dealer has also been notified so that it may import the controlled substances on behalf of InMed.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.

InMed Pharmaceuticals Inc.

Craig Schneider, President and Chief Executive Officer

Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about preparing for human clinical studies for lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) and finalizing the development of their respective proprietary delivery systems; and the value drivers of the company. Although such statements are based on management’s reasonable assumptions, such as the continued existence of the exemption, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: the exemption may be removed or become no longer applicable; anticipated clinical studies may not be conducted as planned, or at all; and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities atwww.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact:
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
604.669.7207
604.683.2506
info@inmedpharma.com
www.inmedpharma.com

0 675

Statement from Health Canada

Expanding on the statement issued on February 20, 2015, Health Canada is delivering the current update:

On February 13, 2015, Health Canada issued a “Notice of Intent to Refuse” to CEN Biotech, Inc. as a rebut to its application for a license to cultivate under the Marihuana for Medical Purposes Regulations (MMPR).

The MMPR states that Health Canada must give proper notice to applicants that it intends to reject for a license. Said applicant is then given 20 days to introduce formal written representations.

The Department has presently notified the company that the decision to deny the application is now certain.

0 1237

Bedrocan receives Health Canada MMPR Production License

Import Permit Issued for Transfer of Genetic Clones from the Netherlands

TORONTO , Feb. 19, 2015 /CNW/ – Bedrocan Cannabis Corp. (BED.V) (“Bedrocan” or the “Company”) announced today that its wholly-owned subsidiary, Bedrocan Canada Inc., has received a second license from Health Canada to allow for the production of medicinal cannabis under the Marihuana for Medicinal Purposes Regulations (“MMPR”). Under the terms of this license, which became effective on February 17, 2015 for a period of one year, Bedrocan can immediately begin domestic production in the first six grow rooms, out of a total of 34, at the Company’s new 52,000 square foot production facility in the Greater Toronto Area . When fully licensed by Health Canada, the facility is capable of producing approximately 4,000 kg of medicinal cannabis per year.

Bedrocan now has two licensed facilities in operation in the Greater Toronto Area . As previously announced on December 3, 2014 , Bedrocan also has an existing Health Canada license, which was renewed for an additional one year term expiring on December 2, 2015 , to import up to 240 kg from the Dutch government’s Office of Medicinal Cannabis. The Company will now begin the transition to full domestic production, constituting Phase II of the Company’s growth strategy.

Furthermore, Health Canada has also issued Bedrocan an import permit to allow for immediate transfer of live genetic clones from Bedrocan BV in the Netherlands to the Company’s domestic production facility. Bedrocan’s import permit from Health Canada follows the issuance of an additional import permit from the Canadian Food Inspection Agency, allowing for the first ever legal import of live cannabis plants into Canada

“We are delighted to have reached this critical milestone in our growth strategy, allowing us to significantly scale up the volume of product we can offer to Canadian patients,” said Marc Wayne , President and CEO. “We remain on schedule to deliver our first production harvest and sale in Q2’2015. In addition, our import strategy will remain in place through transition to full domestic production to ensure a continued, consistent and uninterrupted supply of medicinal cannabis to our patients.”

Bedrocan is the only company in the world capable of offering patients standardized full-bud dried cannabis, containing consistent levels of cannabinoids (the active ingredients) from batch to batch. Product standardization is the only way to  provide physicians and patients with consistency and replicability of therapeutic effect, and thereby enhanced ability to track efficacy, safety and side effects over time. Production at the new domestic facility will be grown from clones that are genetically identical to those developed by Bedrocan BV.

About Bedrocan

Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan’s strains of pharmaceutical-grade cannabis have been used by more than 20,000 patients in seven countries, including Canada . The Company is committed to clinical research with ISO 9001-rated production processes and product development, on an international scale. Bedrocan is one of only two companies currently supplying pharmaceutical-grade medicinal cannabis in Canada . Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol “BED”. www.bedrocan.ca

Forward-Looking Statements

Certain information in this release are forward-looking statements with respect to the development plans and growth targets of the Company. Forward-looking statements consist of statements that are not purely historical, including statements regarding beliefs, plans, expectations or intensions for the future, and include, but not limited to, statements with respect to: (a) the commencement of domestic production of medicinal cannabis by the Company, and capacity for such production; (b) the Company’s plan to scale up the volume of its product available to Canadian patients; and (c) the success of the Company’s import and domestic production strategy.  The basis for the assumptions underlying such statements include that: (i) Bedrocan’s existing licenses will remain in full force and effect, and be renewed upon terms acceptable to Bedrocan in the future; (ii) actual results of the Company’s planned domestic production and development activities will continue to be positive and proceed as planned; (iii) all requisite regulatory and governmental approvals will be received on a timely basis on terms acceptable to the Company, and (iv) economic, political and industry market conditions will be favourable. However, such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including, but not limited to: (1) the risk that domestic production may not be achieved as planned; (2) changes in project parameters as plans evolve; (3) dependence on regulatory approvals and changes in legislation, environmental compliance, community support and the political and economic climate; (4) availability of future financing; and (5) the timely completion of the Company’s production facility and other factors beyond the control of the Company. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.  The Company assumes no obligation to update such information, except as may be required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Bedrocan Cannabis Corp.

Contact:

Cam Battley, Bedrocan Cannabis Corp.
cbattley@bedrocan.ca
+1.905.864.5525
www.bedrocan.ca

Investor relations:
Jennifer Wood,
TMX Equicom
jwood@tmxequicom.com
+1.416.815.0700, ext. 226

 

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com